Literature DB >> 31747462

Direct oral anticoagulants uptake and an oral anticoagulation paradox.

Cormac Kennedy1, Caitriona Ni Choitir2, Sarah Clarke3, Kathleen Bennett4, Michael Barry1,2,3.   

Abstract

Oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation is underutilised. One of the impediments to warfarin therapy is the frequent monitoring required, usually at a specialised warfarin clinic. The advent of direct oral anticoagulants (DOACs) facilitates OAC therapy without an onerous monitoring regimen. This benefit may result in the more significant adoption of DOACs in areas without a warfarin clinic. This study analysed national administrative data for reimbursed pharmacy claims to assess OAC prescribing from 2010 to 2017 and compared the use of DOACs in areas with warfarin clinics compared to those without. Over the study period, the number of patients on OAC increased by 84%, due to a rapid increase in DOAC prescribing. The findings demonstrate that DOACs have resulted in an increase in the overall uptake of OAC therapy in Ireland. However, the increased utilisation was not evidently related to populations underserved by warfarin clinics.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; direct oral anticoagulant; novel oral anticoagulant; warfarin

Mesh:

Substances:

Year:  2020        PMID: 31747462      PMCID: PMC7015756          DOI: 10.1111/bcp.14171

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  39 in total

1.  Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Emily C O'Brien; DaJuanicia N Holmes; Jack E Ansell; Larry A Allen; Elaine Hylek; Peter R Kowey; Bernard J Gersh; Gregg C Fonarow; Christopher R Koller; Michael D Ezekowitz; Kenneth W Mahaffey; Paul Chang; Eric D Peterson; Jonathan P Piccini; Daniel E Singer
Journal:  Am Heart J       Date:  2014-01-04       Impact factor: 4.749

2.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?

Authors:  Peter J Zimetbaum; Amit Thosani; Hsing-Ting Yu; Yan Xiong; Jay Lin; Prajesh Kothawala; Matthew Emons
Journal:  Am J Med       Date:  2010-05       Impact factor: 4.965

3.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.

Authors:  Ying Xian; Emily C O'Brien; Li Liang; Haolin Xu; Lee H Schwamm; Gregg C Fonarow; Deepak L Bhatt; Eric E Smith; DaiWai M Olson; Lesley Maisch; Deidre Hannah; Brianna Lindholm; Barbara L Lytle; Michael J Pencina; Adrian F Hernandez; Eric D Peterson
Journal:  JAMA       Date:  2017-03-14       Impact factor: 56.272

4.  Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: description of successful outcomes.

Authors:  Shane L Jackson; Gregory M Peterson; Murray House; Timothy Bartlett
Journal:  Aust J Rural Health       Date:  2004-10       Impact factor: 1.662

5.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

6.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

7.  Important Changes for Practicing Physicians in the Focused Atrial Fibrillation Guideline Update.

Authors:  Mark S Link
Journal:  Circulation       Date:  2019-02-01       Impact factor: 29.690

8.  Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data.

Authors:  Sarah-Jo Sinnott; Kathleen Bennett; Caitriona Cahir
Journal:  Eur J Clin Pharmacol       Date:  2017-08-17       Impact factor: 2.953

9.  Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.

Authors:  Géric Maura; Cécile Billionnet; Jérôme Drouin; Alain Weill; Anke Neumann; Antoine Pariente
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

10.  Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.

Authors:  Patricia N Apenteng; Haiyan Gao; Fd Richard Hobbs; David A Fitzmaurice
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

View more
  4 in total

1.  Direct oral anticoagulants uptake and an oral anticoagulation paradox.

Authors:  Cormac Kennedy; Caitriona Ni Choitir; Sarah Clarke; Kathleen Bennett; Michael Barry
Journal:  Br J Clin Pharmacol       Date:  2020-01-16       Impact factor: 4.335

2.  Patients' and clinicians' perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis.

Authors:  Yeyenta Mina Osasu; Richard Cooper; Caroline Mitchell
Journal:  BMC Fam Pract       Date:  2021-12-22       Impact factor: 2.497

3.  Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Authors:  Kristina Medlinskiene; Justine Tomlinson; Iuri Marques; Sue Richardson; Katherine Stirling; Duncan Petty
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

4.  Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation.

Authors:  Thomas R Meinel; Mattia Branca; Gian Marco De Marchis; Krassen Nedeltchev; Timo Kahles; Leo Bonati; Marcel Arnold; Mirjam R Heldner; Simon Jung; Emmanuel Carrera; Elisabeth Dirren; Patrik Michel; Davide Strambo; Carlo W Cereda; Giovanni Bianco; Georg Kägi; Jochen Vehoff; Mira Katan; Manuel Bolognese; Roland Backhaus; Stephan Salmen; Sylvan Albert; Friedrich Medlin; Christian Berger; Ludwig Schelosky; Susanne Renaud; Julien Niederhauser; Christophe Bonvin; Michael Schaerer; Marie-Luise Mono; Biljana Rodic; Alexander A Tarnutzer; Pasquale Mordasini; Jan Gralla; Johannes Kaesmacher; Stefan Engelter; Urs Fischer; David J Seiffge
Journal:  Ann Neurol       Date:  2020-10-17       Impact factor: 10.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.